Safety and effectiveness of carotegrast methyl in patients with ulcerative colitis: an interim report of post-marketing surveillance in Japan.
6 affiliations
- 1Department of Internal Medicine, Division of Gastroenterology and Hepatology, The Jikei University School of Medicine, Tokyo, Japan.
- 2Department of Neurology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- 3Medical Department, EA Pharma Co., Ltd, Tokyo, Japan.
- 4Pharmaceutical Development Department, EA Pharma Co., Ltd, Tokyo, Japan.
- 5Department of Post-Marketing Surveillance Pharmacovigilance & Post-Marketing Surveillance, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan.
- 6Internal Medicine for Inflammatory Bowel Disease, Toyama University Hospital, Toyama, Japan.
Abstract
Background
The first multicenter, prospective post-marketing surveillance (PMS) in Japan was conducted to confirm the safety and effectiveness of carotegrast methyl (hereafter referred to as carotegrast) in the routine clinical practice for ulcerative colitis (UC) in Japan. Here, we report the results of the interim analysis of PMS.Methods
The ongoing PMS was initiated in June 2022 and will be continued until May 2028. Study patients are individuals with moderately active UC who were refractory or intolerant to 5-aminosalicylic acid, and who started carotegrast therapy for the first time. An interim analysis was conducted based on the data cut-off (March 27, 2025).Results
Safety and effectiveness analysis sets included 296 and 290 patients, respectively. In the safety analysis set, 36.8% of patients received carotegrast for <8 weeks and 63.2% for ≥8 weeks. The most common reason for treatment discontinuation was inadequate effectiveness in 44.0% of patients who received carotegrast for <8 weeks, and symptom improvement in 66.8% for ≥8 weeks. Adverse drug reactions (ADRs) were reported in 25 patients (8.45%). No serious ADRs, ADRs relevant to progressive multifocal leukoencephalopathy, and central nervous system-related ADRs were reported. No pregnancies were reported. One patient (0.34%) experienced an ADR of pyelonephritis related to infections. The proportions of patients with clinical response, clinical remission and rectal bleeding disappearance (defined by using partial Mayo score) were 146/185 (78.9%), 133/189 (70.4%) and 137/190 (72.1%) after 8 weeks carotegrast administration, respectively.Conclusions
No new safety and effectiveness concerns were identified in the interim analysis for PMS.
Related
- Safety of pairwise co-administration of influenza, PCV20, and RZV vaccines in adults aged ≥50 years: a post-marketing surveillance study using VAERS data
- Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
- Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission
- A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
- Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE).
BibTeX
@article{saruta2026safety,
title = {{Safety and effectiveness of carotegrast methyl in patients with ulcerative colitis: an interim report of post-marketing surveillance in Japan.}},
author = {Masayuki Saruta and Yoshiharu Miura and Mie Iwaida and Minami Umeyama and Shinsuke Kurosu and Kiyotoshi Kuramoto and Kenji Watanabe},
journal = {Crohn's \& colitis 360},
year = {2026},
month = sep,
doi = {10.1093/crocol/otag105},
url = {https://europepmc.org/article/MED/42846544},
note = {CC BY},
}
RIS
TY - JOUR
TI - Safety and effectiveness of carotegrast methyl in patients with ulcerative colitis: an interim report of post-marketing surveillance in Japan.
AU - Masayuki Saruta
AU - Yoshiharu Miura
AU - Mie Iwaida
AU - Minami Umeyama
AU - Shinsuke Kurosu
AU - Kiyotoshi Kuramoto
AU - Kenji Watanabe
PY - 2026
DA - 2026/09/18
JO - Crohn's & colitis 360
DO - 10.1093/crocol/otag105
UR - https://europepmc.org/article/MED/42846544
AB - Background The first multicenter, prospective post-marketing surveillance (PMS) in Japan was conducted to confirm the safety and effectiveness of carotegrast methyl (hereafter referred to as carotegrast) in the routine clinical practice for ulcerative colitis (UC) in Japan. Here, we report the results of the interim analysis of PMS.Methods The ongoing PMS was initiated in June 2022 and will be continued until May 2028. Study patients are individuals with moderately active UC who were refractory or intolerant to 5-aminosalicylic acid, and who started carotegrast therapy for the first time. An interim analysis was conducted based on the data cut-off (March 27, 2025).Results Safety and effectiveness analysis sets included 296 and 290 patients, respectively. In the safety analysis set, 36.8% of patients received carotegrast for <8 weeks and 63.2% for ≥8 weeks. The most common reason for treatment discontinuation was inadequate effectiveness in 44.0% of patients who received carotegrast for <8 weeks, and symptom improvement in 66.8% for ≥8 weeks. Adverse drug reactions (ADRs) were reported in 25 patients (8.45%). No serious ADRs, ADRs relevant to progressive multifocal leukoencephalopathy, and central nervous system-related ADRs were reported. No pregnancies were reported. One patient (0.34%) experienced an ADR of pyelonephritis related to infections. The proportions of patients with clinical response, clinical remission and rectal bleeding disappearance (defined by using partial Mayo score) were 146/185 (78.9%), 133/189 (70.4%) and 137/190 (72.1%) after 8 weeks carotegrast administration, respectively.Conclusions No new safety and effectiveness concerns were identified in the interim analysis for PMS.
SN - 2631-827X
ER -